PT-141 Research
Melanocortin Receptor Research Peptide
melanocortin pathways
Weight and Wellness
Stress and Anxiety
Libido, Hormones and Menopause
Nur Bildungsinformationen. Experimentelle Anwendungen haben möglicherweise keine FDA-Zulassung. Keine medizinische Beratung oder Behandlungsplan.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its activity at MC3 and MC4 receptors in the central nervous system. A pharmaceutical version (Vyleesi) received FDA approval for hypoactive sexual desire disorder in premenopausal women. Research covers several signaling areas:
Forschungsbereiche
Melanocortin Receptor Signaling
Research focuses on PT-141's activity at MC3 and MC4 receptors and its downstream effects on dopamine and norepinephrine signaling pathways.
Sexual Function Pathway Research
Studies examine its role in libido-related neural pathways, sexual arousal signaling, and desire-related CNS activity in both men and women.
Mood & Motivation Signaling
Researchers investigate its influence on dopaminergic pathways involved in mood, motivation, and reward-system signaling research.
Energy & CNS Activation Research
Studies explore its role in central nervous system activation signaling, alertness pathways, and energy-related neurological research.
A pharmaceutical version (Vyleesi/bremelanotide) is FDA-approved for HSDD in premenopausal women. PT-141 as a research peptide is investigational. Not medical advice.
Haben Sie Fragen zu PT-141?
Fordern Sie eine kostenlose Beratung an, um Fragen zu stellen und mehr über diesen Forschungsbereich zu erfahren.
Kostenlose Beratung anfordern